ACER - Acer Therapeutics begins phase 3 trial of Edsivo to treat rare genetic disorder treatment

Acer Therapeutics (NASDAQ:ACER) said on Monday it had begun patient screening in its Phase 3 trial of Edsivo to treat patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS), a rare genetic disorder that can cause blood vessels to fatally rupture. The main goal of the trial is to check whether the therapy, Edsivo, reduces the occurrence of vEDS-related clinical events requiring medical attention, including fatal and non-fatal cardiac or arterial events, uterine rupture, intestinal rupture, unexplained sudden death, compared to placebo. Acer plans to enroll about 150 COL3A1-positive vEDS patients in the U.S.

For further details see:

Acer Therapeutics begins phase 3 trial of Edsivo to treat rare genetic disorder treatment